Biotek-snakken — April 2026
-
Initiator Pharma A/S rapporterer fremskridt i patientrekrutteringen til fase 2a-studie i vulvodyni https://www.nordnet.dk/markedet/nyheder/4a963de2-45da-4f01-9de5-b12683953745
-
Initiator Pharma A/S: Enrolment on track - fair value range 6,8–9,3 SEK (DNB Carnegie)
Recruitment in the important vulvodynia study appears to be on track, with half of the planned patients already dosed. We find the positive development encouraging. We believe a positive outcome could represent a key value inflection point, and estimate peak sales of approximately USD1.6bn, risk-adjusted at a 15% LOA. https://access.dnbcarnegie.com/publication/e46d158f-68fe-43f0-58cb-08dea508df61
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind